MELK inhibitor - Genosco
Alternative Names: Maternal embryonic leucine zipper kinase inhibitor - GenoscoLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Genosco
- Class Antineoplastics; Small molecules
- Mechanism of Action MELK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Triple-negative-breast-cancer in USA
- 09 Sep 2020 Early research in Triple negative Breast cancer in USA (unspecified route) before September 2020 (Genosco pipeline, September 2020)